Board summary
Key figures
59,946
Registered population
56.1% aged 18–64
26.0%
Aged 65+
ICB 14.9% · England 17.9%
3.6%
In IMD quintile 1
ICB 40.7% · England 21.0%
~1,979
Core20 residents (est.)
Resident basis; registered basis ~1,961 · see page 3
11,325
Hypertension register
+6.38% in 3 yrs · England +5.60%
529
SMI register
15.8% of Stockport (LAD)'s
1,352
COPD register
Reviews -0.32% in 3 yrs
Forecast to 2030
12,971
Hypertension patients, 2030
+1,646 on today
68.3%
QRISK ≥20% on statins, 2030
+3.08pp over 3 yrs
6.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Deprivation concentrates at Archwood Medical Practice.
Archwood Medical Practice has a 17.9% Core20 share (1,369 estimated patients), which may warrant targeted outreach if local register audits confirm unmet need.
Lipid therapy trails England at higher unit cost.
Lipid therapy in QRISK >= 20% (61.6% vs England 63.6%) and CKD (68.0% vs 70.3%) trails England, while unit cost is £2.10 vs £1.86.
Strong blood pressure and chronic review baselines.
Hypertension control (78.6% vs England 70.3%), COPD reviews (86.6% vs 76.4%) and heart failure reviews (87.2% vs 78.5%) exceed England, though 18 trends trail.
Population, age and ethnicity
Patients aged 65 and over reach 26.0%, well above borough and national levels
Across eight practices, the PCN registers 59,946 patients: 26.0% (15,578) are aged 65+, against 19.7% in Stockport (LAD), 14.9% in NHS Greater Manchester Integrated Care Board, and 17.9% in England. Working-age adults (18-64) comprise 56.1% (33,645) and children (0-17) 17.9% (10,723). ONS projected list growth to 2030 is 0.6% (LAD 1.1%, ICB 1.6%, England 2.3%; unverified method). Registered lists differ from resident Census data, where Gypsy or Irish Traveller (0.0%) and Roma (0.0%) match LAD (0.0%, 0.0%) and trail the ICB (0.1%, 0.1%) and England (0.1%, 0.2%).
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Stockport (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Stockport LA) | 2,072 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Stockport LA) | 919 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Stockport LA) | 23.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 3.6% overall and concentrates sharply in Archwood Medical Practice
Stockport East and South PCN averages IMD decile 7.1, above Stockport (LAD) (6.4), NHS Greater Manchester Integrated Care Board (4.5) and England (5.5). Core20 prevalence is 3.6%, below Stockport (LAD) (16.1%), the ICB (40.7%) and England (21.0%). Practice shares weight to 3.3% versus 1,979 estimated Core20 residents. Deprivation concentrates heavily: Archwood Medical Practice records 17.89% share (1,369 estimated patients), Chadsfield Medical Practice 5.26% (344), and Marple Cottage Surgery 2.16% (248), while five practices record 0.0%. Prioritise targeted outreach and preventive checks on practices carrying the PCN's Core20 caseload.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
529
SMI register
0.88% recorded prevalence
291
Learning disability register
0.48% recorded prevalence
27
Care homes, 977 beds
In the PCN catchment
9.5%
Provide unpaid care
Stockport (LAD), Census 2021
Recorded severe mental illness prevalence is 0.9% (529 patients), below Stockport (LAD) (1.0%), NHS Greater Manchester Integrated Care Board (1.1%), and England (1.0%). Learning disability prevalence is 0.5% (291 patients) versus 0.6% across Stockport (LAD), the ICB, and England. Catchment care homes total 27 with 977 beds. Lower recorded prevalence across comparators may reflect diagnostic coding patterns, which register audits would test.
Severe mental illness: physical health checks
Physical checks for severe mental illness exceed England, including blood pressure at 89.5% (England 83.4%), alcohol recording at 89.9% (England 81.8%), and BMI at 88.8% (England 82.1%). Over 2023 to 2025, blood pressure recording rose +1.0 pp (England +4.4 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
11,325
Hypertension register
+6.38%
Register growth, 3 yrs
Stockport (LAD) +4.99% · England +5.60%
+0.60pp
BP control, under 80
≤140/90 · −0.83pp aged 80+
+1,646
More patients by 2030
Forecast 12,971 (21.30%)
Hypertension case-finding and control
The PCN records 11,325 patients on its hypertension register, representing a prevalence of 18.8%, above Stockport (16.2%), NHS Greater Manchester ICB (14.4%), and England (15.2%). Blood pressure control remains strong: 78.6% of hypertensive patients are treated to target, compared with 73.6% in Stockport, 71.4% in the ICB, and 70.3% in England. Among hypertensive patients aged 80 and over, 86.8% had a blood pressure reading <= 150/90 mmHg (England 81.2%), though this fell 0.9% over 2023 to 2025 (England +2.2%).
Lipids and statins
Lipid therapy trails England in QRISK ≥ 20% (61.6% vs 63.6%), CKD (68.0% vs 70.3%), and diabetes without CVD (72.3% vs 73.2%) or with CVD (81.9% vs 84.4%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 139,275 | £2.10 | £1.94 | £1.86 | £292,478 |
| Cardiovascular (all), 2025 | 194,754 | £3.81 | £3.15 | £3.33 | £742,013 |
For lipid-regulating drugs, the PCN prescribed 139,275 items at £2.10 per item, above Stockport (£1.99), NHS Greater Manchester ICB (£1.94), and England (£1.86). This represents £33,426 more than at England's unit cost, across 139,275 items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−3.63%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.88%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.4% (4,226 patients; England 6.6%) and COPD prevalence is 2.2% (1,352 patients; England 1.9%). Recorded reviews exceed England in COPD (86.6% vs 76.4%) and asthma (70.2% vs 65.7%). Over 2023 to 2025, asthma reviews fell 3.6% (England +4.4%), leaving about 1,300 unreviewed patients (modelled gap 1,261). Asthma management prescribing for ages 5-19 reaches 1,720 per 1,000 (England 1,488).
Cancer register and children's immunisation
Cancer register prevalence is 5.3% (3,167 patients; England 3.8%). In Q1 2025/26, childhood 6-in-1 coverage is 96.9% and age-5 MMR1 is 99.3%, both above the 95.0% target. However, age-5 MMR2 is 94.8% (4.5 pp below MMR1) and 4-in-1 pre-school booster is 92.5%, trailing the 95.0% target by 0.2 pp and 2.5 pp respectively.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2 (England 55.3%), 19.4 pp below the 75.0% national ambition (2,268.2 extra cases needed), gaining +3.1 pp since 2013 (52.4%). Known-stage coverage was 70.8% (11,679 of 16,492 cases; England 67.0%). Site staging varies: breast reached 82.5%, bowel 46.3%, and lung 40.4%. At PCN level, cancer prevalence is 5.3% (3,167 patients) with 3-year register growth of +8.0% (England +9.0%), trailing at Beech House Medical Pract (+1.6%) and Archwood Medical Practice (+3.6%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Stockport NHS Foundation Trust, 28-day faster diagnosis was 83.2% (8.2 pp above the 75.0% standard) and 31-day combined treatment was 97.4% (1.4 pp above the 96.0% standard), but 62-day referral to treatment was 74.7% (10.3 pp below the 85.0% standard). Across NHS Greater Manchester Integrated Care Board, 28-day faster diagnosis was 79.5% (4.5 pp above standard) and 31-day treatment was 96.5% (0.5 pp above standard), while 62-day referral to treatment was 75.7% (9.3 pp below standard). Slower 62-day pathways reflect wider system operational pressure rather than PCN-level performance.
| Pathways within standard (%) | Stockport | Tameside and Glossop Integrated Care | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 83.21 | 82.48 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 97.39 | 96.25 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 74.67 | 76.77 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Stockport | Tameside and Glossop Integrated Care | Manchester | England |
|---|---|---|---|---|
| MRI | 1.41 | 0.00 | 11.68 | 21.40 |
| CT | 2.93 | 0.18 | 14.66 | 9.92 |
| Echocardiography | 17.46 | 0.00 | 4.91 | 28.48 |
| Colonoscopy | 5.53 | 1.51 | 4.51 | 30.83 |
| Gastroscopy | 5.31 | 5.45 | 29.35 | 29.02 |
| All 15 DM01 tests | 14.08 | 0.80 | 8.98 | 23.14 |
| Community services activity | Stockport residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 57,085 | 573,310 |
| Referrals | 10,690 | 94,470 |
| Patients with a contact | 16,950 | 183,535 |
Community services (residents of Stockport), Jun 2026 (provisional). In Stockport borough, older adults account for the substantial majority of community health activity: 60.6% of all recorded community service contacts (34,585 of 57,085 contacts) were with residents aged 65 and over (provisional Jun 2026 data). Because community activity is captured only at local authority resident level, it reflects broader system utilisation rather than PCN-specific delivery, consistent with supporting an ageing population.
Practice variation and patient experience
Phone contact ease spans 29.4 pp across practices alongside wide vaccination achievement variation
In 2025/26, QOF overall achievement ranged from 93.2% at Archwood Medical Practice to 100.0% at Marple Bridge Surgery and Marple Cottage Surgery (England 92.5%). However, vaccination and immunisation achievement showed a 56.5 pp spread, spanning 43.5% at Archwood Medical Practice to 100.0% at Marple Bridge Surgery, suggesting immunisation delivery varies considerably between member practices.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| High Lane | 115 | 0.0 | 98.3% | 83.1% | 98.7% |
| Marple Bridge | 108 | 0.0 | 94.5% | 71.2% | 96.2% |
| Beech House | 99 | 0.0 | 71.6% | 68.4% | 91.9% |
| Marple Cottage | 97 | 2.2 | 93.5% | 82.4% | 91.0% |
| Marple Medical | 112 | 0.0 | 88.2% | 79.0% | 90.1% |
| Springfield | 137 | 0.0 | 88.6% | 83.7% | 89.9% |
| Chadsfield | 108 | 5.3 | 68.9% | 81.9% | 89.6% |
| Archwood Medical | 107 | 17.9 | 87.6% | 84.1% | 88.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
18 of 25 tracked three-year trends trail England despite high current clinical baselines
Over three years (2023 to 2025), 18 of 25 measures trail England's change. The widest relative lags are heart failure reviews (-1.6% vs England +8.7%) and asthma reviews (-3.6% vs England +4.4%), alongside hypertension control (-0.7% vs England +3.6%) and diabetes statins (-1.2% vs England +2.1%). Mental health blood pressure checks rose +1.0 pp (England +4.4 pp). Conversely, cervical screening rose +1.0% (England -1.0%) and smoking support rose +0.2 pp (England +0.1 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
Hypertension treated to target
BP check (SMI)
Diabetes statin (no CVD)
Cervical screening
Smoking support (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Stockport (LAD) | Asset | PCN | Stockport (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 27 (977 beds) | n/a | Schools (catchment) | 71 | n/a |
| Children's centres | no data | 2 | Places of worship | 43 | 135 |
| Libraries | 5 | 12 | Food banks (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 14 | 61 | Primary academies | 11 | 23 |
| Special schools | 1 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Across the 4,226-patient asthma register (7.4% prevalence), the review rate is 70.2% (England 65.7%), falling 3.6% over 2023 to 2025 (England +4.4%), leaving 1,261 unreviewed patients (about 1,300). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Lipid-modifying therapy and prescribing review
Lipid therapy trails England in QRISK >= 20% (61.6% vs 63.6%), CKD (68.0% vs 70.3%) and diabetes (72.3% vs 73.2%; with CVD 81.9% vs 84.4%); unit cost is £2.10 vs England £1.86 (£33,426 more across 139,275 items). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Learning disability register validation
Recorded learning disability prevalence is 0.5% (291 patients) across the 59,946 list, below 0.6% in Stockport (LAD), NHS Greater Manchester Integrated Care Board and England, giving a modelled gap of +44 to +61 patients. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register review (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check audit (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Older hypertensive patient review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register review (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Telephony and triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Lipid-modifying therapy and prescribing review (p12) | Hypertension register · Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
